Patient Host Type & Antibiotic Options
Emergency Department
Evidence Based Outcome Center

**Normal Immunologic**
- Any of the following:
  - Oncology patient without CVL/PICC and off chemo ≥ 3 months
  - Chronic illness but normal immunity (GI, Seizures, etc)
  - No past medical history
  - Adrenal insufficiency

**Moderate Risk Immunologic**
- Any of the following:
  - Oncology patient with CVL/PICC & off chemo ≥ 3 months
  - Asplenic
  - Chronic neutropenia
  - Sickle Cell Disease
  - Recent/current history of immunosuppressive agents
  - Normal Immunologic host with CVL
  - Biologics

**High Risk Immunologic**
- Any of the following:
  - Oncology
  - Oncology patient off Chemo < 3 months
  - Prednisone Equivalent Steroids (2/mg/kg/day)+ ≥ 14 days
  - Immunodeficiency
  - Transplant patients
  - TPN dependent
  - Hemodialysis Catheter
  - Aplastic Anemia

**Antibiotic Therapy:**
- Ceftriaxone: 75 mg/kg/dose x1 | Max dose: 2 gm
- Cephalosporin Allergy:
  - Aztreonam: 50 mg/kg/dose x1 | Max dose: 2 gm
  - AND
  - Vancomycin: 15 mg/kg/dose | Max dose: 1 gm
- Vancomycin: 15 mg/kg/dose | Max dose: 1 gm

- Cefepime: 50 mg/kg/dose x1 | Max dose: 2 gm
- Cephalosporin Allergy:
  - Aztreonam: 50 mg/kg/dose x1 | Max dose: 2 gm
  - AND
  - Vancomycin: 15 mg/kg/dose | Max dose: 1 gm
- Vancomycin: 15 mg/kg/dose | Max dose: 1 gm

- Meropenem: 40 mg/kg/dose x1 | Max dose: 2 gm
- Cephalosporin Allergy:
  - Aztreonam: 50 mg/kg/dose x1 | Max dose: 2 gm
  - AND
  - Vancomycin: 15 mg/kg/dose | Max dose: 1 gm
- Vancomycin: 15 mg/kg/dose | Max dose: 1 gm
## Patient Host Type & Antibiotic Options

### Emergency Department

**Evidence Based Outcome Center**

### Emergency Department Pathway

#### Host Type

<table>
<thead>
<tr>
<th>Any of the following:</th>
<th>Hemodynamically Stable</th>
<th>Hemodynamically Unstable</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Normal Immunologic</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology patient without CVL and off chemo ≥ 3 months</td>
<td>Ceftriaxone: 75 mg/kg/dose x1</td>
<td>Vancomycin: 15 mg/kg/dose Max dose: 1 gm</td>
</tr>
<tr>
<td>No past medical history</td>
<td>Max dose: 2 gm</td>
<td></td>
</tr>
<tr>
<td>Adrenal insufficiency</td>
<td>AND Vancomycin: 15 mg/kg/dose Max dose: 1 gm</td>
<td></td>
</tr>
<tr>
<td>Chronic illness but normal immunity (GI, Seizures, etc)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Moderate Risk Immunologic</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology patient with CVL &amp; off chemo ≥ 3 months</td>
<td>Aztreonam: 50 mg/kg/dose x1</td>
<td>Vancomycin: 15 mg/kg/dose Max dose: 1 gm</td>
</tr>
<tr>
<td>Asplenic</td>
<td>Max dose: 2 gm</td>
<td></td>
</tr>
<tr>
<td>Chronic neutropenia</td>
<td>AND Vancomycin: 15 mg/kg/dose Max dose: 1 gm</td>
<td></td>
</tr>
<tr>
<td>Sickle Cell Disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recent/current history of immunosuppressive agents</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal Immunologic host with CVL Biologics</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>High Risk Immunologic</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology</td>
<td>Cefepime: 50 mg/kg/dose x1</td>
<td>Max dose: 2 gm</td>
</tr>
<tr>
<td>Oncology patient off Chemo &lt; 3 months</td>
<td>Max dose: 2 gm</td>
<td></td>
</tr>
<tr>
<td>Prednisone Equivalent Steroids (2/mg/kg/day)+ ≥ 14 days</td>
<td>AND Vancomycin: 15 mg/kg/dose Max dose: 1 gm</td>
<td></td>
</tr>
<tr>
<td>Immunodeficiency</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transplant patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TPN dependent</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemodialysis Catheter</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aplastic Anemia</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Antimicrobial Therapy

**Cephalosporin Allergy**

- Aztreonam: 50 mg/kg/dose x1
- Max dose: 2 gm
- AND Vancomycin: 15 mg/kg/dose
- Max dose: 1 gm

- Cefepime: 50 mg/kg/dose x1
- Max dose: 2 gm
- AND Vancomycin: 15 mg/kg/dose
- Max dose: 1 gm

- Meropenem: 40 mg/kg/dose x1
- Max dose: 2 gm
- AND Vancomycin: 15 mg/kg/dose
- Max dose: 1 gm

For questions concerning this pathway, [Click Here]

Last Updated September 21, 2017
EBOC Project Owners: Tina Chu, MD & Michael Gorn, MD

Approved by the Evidence-Based Outcomes Center

Revision History
Date Approved: July 2017
Next Review Date: July 2020

EBOC Team:
Tina Chu, MD
Michael Gorn, MD
Dory Collette, RN
Amy Fowler, MD
Marisol Fernandez, MD
Sarmistha Hauger, MD
Donald Murphey, MD
Katherine Merkel, PharmD
Denita Lyons, RN
Patrick Boswell

EBOC Committee:
Sarmistha Hauger, MD
Terry Stanley, DNP, RN, NE-BC
Deb Brown, RN
Sujit Iyer, MD
Tory Meyer, MD
Nilda Garcia, MD
Meena Iyer, MD
Michael Auth, DO

Updated 9-21-2017: Removed Cytic Fibrosis patients from high risk immunologic patient type.

LEGAL DISCLAIMER: The information provided by Dell Children’s Medical Center of Texas (DCMCT), including but not limited to Clinical Pathways and Guidelines, protocols and outcome data, (collectively the “Information”) is presented for the purpose of educating patients and providers on various medical treatment and management. The Information should not be relied upon as complete or accurate; nor should it be relied on to suggest a course of treatment for a particular patient. The Clinical Pathways and Guidelines are intended to assist physicians and other health care providers in clinical decision-making by describing a range of generally acceptable approaches for the diagnosis, management, or prevention of specific diseases or conditions. These guidelines should not be considered inclusive of all proper methods of care or exclusive of other methods of care reasonably directed at obtaining the same results. The ultimate judgment regarding care of a particular patient must be made by the physician in light of the individual circumstances presented by the patient. DCMCT shall not be liable for direct, indirect, special, incidental or consequential damages related to the user’s decision to use this information contained herein.